Improving anti–CTLA-4 therapies through peptide masking and fragment crystallizable non‑fucosylation: preclinical characterization of three novel antibodies
Anti-CTLA-4 NF-PB has enhanced antitumor activity, efficacy, and reduced peripheral activity in preclinical models, and has the potential to provide therapeutic benefit in solid tumors.
Authors
- Mona Yazdani
- Wei Hu (ORCID: https://orcid.org/0000-0001-9332-9670)
- Alessandra Vaccaro (ORCID: https://orcid.org/0000-0003-3515-4117)
- Alan J. Korman (ORCID: https://orcid.org/0000-0002-1142-8542)
- Joshua Dobroff
- Monika Pradhan
- Amy Jhatakia (ORCID: https://orcid.org/0000-0001-6855-5342)
- Yun Wei (ORCID: https://orcid.org/0009-0002-2886-6503)
- John Engelhardt
- Tina Cascone (ORCID: https://orcid.org/0000-0003-3008-5407)
- Courtni Newsome
- Felix Findeisen
- Haiping Guo (ORCID: https://orcid.org/0009-0005-1675-7811)
- Remie Gail Z. Mandawe
- Neha Gupta (ORCID: https://orcid.org/0000-0003-3945-0968)
- Ke Xu (ORCID: https://orcid.org/0000-0002-6602-3382)
- John T. Le
- L L Leung
- Anandaroop Mukhopadhyay
- Jack Lohre
- Karen Price (ORCID: https://orcid.org/0000-0002-2318-2455)
- Amy Hammell
- Cheuk Hong Leung
- Shaun O'Brien
- Mohammed Nasser
- Michael Wang
- Lili Chen
- Xin Sun
- Heather Y. Lin
- Nicholas Wilson
- Mark Selby
- Kyeongah Kang
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Bristol-Myers Squibb (Germany) (DE)
- Bristol-Myers Squibb (United States) (US)
- Bristol-Myers Squibb (United Kingdom) (GB)
- Bristol-Myers Squibb (Sweden) (SE)
- Bristol-Myers Squibb (Belgium) (BE)
- The Bristol-Myers Squibb Children's Hospital (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-03-16
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-1230
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00